Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651714 · ClinicalTrials.gov registry record · Phase 2
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 20
- Study locations
NCT02651714: Completed Phase 2 study of Atopic Dermatitis, sponsored by Vanda Pharmaceuticals.
NCT02651714 is a Phase 2 study of Atopic Dermatitis that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 168 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02651714, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
Primary Outcome
Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left endpoint was marked "no itch" (0 mm) and in the right endpoint was marked "worst imaginable itch" (100 mm).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tradipitant
Study Locations (20)
California
- Vanda Investigational Site - Encinitas
- Vanda Investigational Site - Encino
- Vanda Investigational Site - Lomita
- Vanda Investigational Site - San Diego
- Vanda Investigational Site - San Diego
Florida
- Vanda Investigational Site - Miami
- Vanda Investigational Site - Miami
- Vanda Investigational Site - Ormond Beach
North Carolina
- Vanda Investigational Site - High Point
- Vanda Investigational Site - Wilmington
- Vanda Investigational Site - Winston-Salem
New York
- Vanda Investigational Site - New York
- Vanda Investigational Site - New York
Georgia
- Vanda Investigational Site - Columbus
Indiana
- Vanda Investigational Site - Plainfield
Louisiana
- Vanda Investigational Site - Crowley
Missouri
- Vanda Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2016-01-19 |
| Est. Completion | 2017-08-04 |
| Phase | Phase 2 |
What the finished NCT02651714 record still lists
NCT02651714 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02651714 names 20 study sites across 11 states, led by California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02651714 about?
NCT02651714 is a clinical study titled "Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis". This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
What is the current status of trial NCT02651714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2016-01-19. Estimated completion is 2017-08-04.
What conditions does trial NCT02651714 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT02651714?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT02651714?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02651714 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02651714's enrollment target sits among peer trials
168 67th of 150 higher than 84 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI